Menu
Search
|

Menu

Close
X

H Lundbeck A/S LUN.CO (Copenhagen Stock Exchange)

469.00 DKK
-6.90 (-1.45%)
As of 9:31 AM EDT
chart
Previous Close 475.90
Open 474.10
Volume 188,664
3m Avg Volume 394,348
Today’s High 475.20
Today’s Low 466.50
52 Week High 477.70
52 Week Low 280.80
Shares Outstanding (mil) 199.10
Market Capitalization (mil) 94,750.94
Forward P/E 29.17
Dividend (Yield %) 8.00 ( 1.68 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.94 Mean rating from 17 analysts

KEY STATS

Revenue (mm, DKK)
FY18
4,585
FY17
17,234
FY16
15,634
FY15
14,594
EPS (DKK)
FY18
6.034
FY17
13.254
FY16
6.137
FY15
-28.969
*Note: Units in Millions of Danish Krone
**Note: Units in Danish Krone

KEY RATIOS

Price to Earnings (TTM)
vs sector
29.17
34.18
Price to Sales (TTM)
vs sector
5.38
8.57
Price to Book (MRQ)
vs sector
8.13
4.35
Price to Cash Flow (TTM)
vs sector
21.29
22.78
Total Debt to Equity (MRQ)
vs sector
0.51
17.37
LT Debt to Equity (MRQ)
vs sector
0.51
12.92
Return on Investment (TTM)
vs sector
25.58
13.17
Return on Equity (TTM)
vs sector
30.17
15.15

EXECUTIVE LEADERSHIP

Lars Rasmussen
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Anders Goetzsche
Interim Chief Executive Officer, Chief Financial Officer, Executive Vice President, Since 2017
Salary: kr.4,300,000.00
Bonus: kr.2,300,000.00
Lene Skole-Soerensen
Deputy Chairman of the Board, Since 2015
Salary: --
Bonus: --
Peter Anastasiou
Executive Vice President, North America, Since 2017
Salary: --
Bonus: --
Lars Bang
Executive Vice President, Supply Operations & Engineering, Since
Salary: kr.3,800,000.00
Bonus: kr.1,700,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

Ottiliavej 9
VALBY     2500

Phone:

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.

SPONSORED STORIES